Compare HAPN & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAPN | ZYME |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2008 | 2022 |
| Metric | HAPN | ZYME |
|---|---|---|
| Price | $15.80 | $29.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $23.88 | ★ $42.43 |
| AVG Volume (30 Days) | ★ 2.5M | 1.2M |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.78 | 33.33 |
| EPS | ★ 1.44 | 1.08 |
| Revenue | ★ $314,702,000.00 | $105,965,000.00 |
| Revenue This Year | N/A | $195.79 |
| Revenue Next Year | $21.71 | $14.68 |
| P/E Ratio | ★ $10.94 | $29.51 |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $13.73 | $18.20 |
| 52 Week High | $21.25 | $31.97 |
| Indicator | HAPN | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 53.65 | 57.38 |
| Support Level | $13.82 | $22.23 |
| Resistance Level | $21.25 | $31.34 |
| Average True Range (ATR) | 0.67 | 1.34 |
| MACD | 0.16 | 0.19 |
| Stochastic Oscillator | 67.04 | 58.42 |
Happen Inc is a U.S. digital marketplace bank focused on the Motivated Middle - high FICO, high-income borrowers actively managing their financial lives. The bank's success is fueled by evolved credit underwriting, a proprietary technology platform, and a marketplace bank model that generates compelling revenue through loan sales, net interest income, and fee-based services.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.